Please login to the form below

Not currently logged in
Email:
Password:

Oliver Rausch to lead translational research partnership efforts at NIHR

Has experience at UCB, GSK and Cellzome

NIHR Dr Oliver RauschDr Oliver Rausch has been appointed programme director of the UK's National Institute for Health Research translational research partnerships.

As part of the NIHR's Office for Clinical Research Infrastructure (NOCRI), the partnerships was created to support collaboration between industry, the NHS and academia in early and exploratory research for products with the potential to have a direct effect on improving healthcare.

Efforts currently cover two areas, inflammatory respiratory disease and joint and related inflammatory diseases, both of which shall be overseen by Dr Rausch.

He brings industry experience to the role having spent the past 15 years working at pharma companies across Europe.

Most recently, he was VP biology at Cellzome, and he has further experience as director, new chemical entities biology at UCB and as an investigator with GlaxoSmithKline (GSK).

Prior to joining the industry, Dr Rausch was a postdoctoral scientist at the Institute of Cancer Research in London.

“Oliver's appointment will strengthen the development of the Partnerships and underpins NOCRI's commitment to clear and streamlined access to the UK's world-leading clinical research infrastructure,” said Mark Samuels, managing director of NOCRI.

14th September 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics